Athenex HQ is in Buffalo, but its power structure is not

Athenex began picking up serious steam about five years ago under the direction of CEO Johnson Lau and then-chief operating officer Flint Besecker. The company long had promising science in the development of cancer therapies, but its ambitious international business model started attracting large sums of foreign investment. That prompted public concern from Western New York investors and government officials that a homegrown company – formerly called Kinex Pharmaceuticals – might leave the…
Source: Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Publication date: Available online 20 May 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Xu Cheng, Dapeng Li, Min Sun, Le He, Yan Zheng, Xin Wang, Rupei TangAbstractChemotherapeutic drugs have a series of limitations in the conventional clinical treatments, mainly including serious adverse effects and multidrug resistance (MDR). Herein, we developed a pH-sensitive polymeric nanoparticle with using poly(ortho ester urethanes) copolymers for co-delivering doxorubicin (DOX) and pyrrolidinedithiocarbamate (PDTC) to settle these problems. Dual-drug-loaded nanoparticles were nano-sized (˜220 nm) with t...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: 15 August 2019Source: Journal of Alloys and Compounds, Volume 797Author(s): D.I. Tishkevich, I.V. Korolkov, A.L. Kozlovskiy, M. Anisovich, D.A. Vinnik, A.E. Ermekova, A.I. Vorobjova, E.E. Shumskaya, T.I. Zubar, S.V. Trukhanov, M.V. Zdorovets, A.V. TrukhanovAbstractMagnetic nanoparticles based on Fe3O4 and their modifications of surface with therapeutic substances are of great interest, especially drug delivery for cancer therapy includes boron-neutron capture therapy. The results of boron-rich compound (carborane borate) attachment to previously aminated by (3-aminopropyl)-trimethoxysilane iron oxide nano...
Source: Journal of Alloys and Compounds - Category: Chemistry Source Type: research
Merck&Co. Inc., looking to strengthen its pipeline of cancer therapies, entered into a definitive agreement Tuesday to acquire Peloton Therapeutics in a deal that includes an upfront payment of $1.05 billion. Shareholders of Peloton will also be eligible to receive up to an additional $1.15 billion if regulatory and sales milestones are achieved for products the Dallas based company has in development. Peloton's lead new drug candidate is in late stage clinical testing as a potential treatment…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: July–August 2019Source: Reports of Practical Oncology &Radiotherapy, Volume 24, Issue 4Author(s): Marika Musielak, Igor Piotrowski, Wiktoria M. SuchorskaAbstractOver the past two decades nanotechnology has become an important part of novel medical research. Researchers have made great progress in developing nanotechnology applications used for detecting and treating oncological diseases. Recently, many research groups have focused on the use of superparamagnetic iron oxide nanoparticles (SPIONs) in cancer treatment. Due to the range of therapeutic properties and possibilities of various modifica...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
New J. Chem., 2019, Advance Article DOI: 10.1039/C9NJ01249D, PaperChengkang Su, Huiqing Zhong, Haolin Chen, Yanxian Guo, Zhouyi Guo, Deqiu Huang, Wen Zhang, Qiang Wu, Biwen Yang, Zhiming Liu Black phosphorus –polypyrrole nanosheets with superimposed NIR absorption have been fabricated as the novel nanotherapeutic agent for enhanced NIR photothermal cancer therapyin vitro andin vivo. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ Abstract INTRODUCTION: Individuals with chronic hepatitis B virus (HBV) infection or past exposure to HBV infection have a substantial risk of reactivation during immunosuppressive cancer therapy. HBV reactivation can lead to liver failure, cancer treatment interruption or death. Clinical concordance with screening and treatment guidelines is inconsistent in practice, and existing international guidelines are not specific to the Australian context. We developed an Austra...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
AbstractSphingosine-1-phosphate (S1P) can regulate several physiological and pathological processes. S1P signaling via its cell surface receptor S1PR1 has been  shown to enhance tumorigenesis and stimulate growth, expansion, angiogenesis, metastasis, and survival of cancer cells. S1PR1-mediated tumorigenesis is supported and amplified by activation of downstream effectors including STAT3, interleukin-6, and NF-κB networks. S1PR1 signaling can also trigge r various other signaling pathways involved in carcinogenesis including activation of PI3K/AKT, MAPK/ERK1/2, Rac, and PKC/Ca, as well as suppression of cyc...
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
In conclusion, drug-conjugated micellar nanoparticles are more desirable for SDT because of accelerated ROS production and drug protection from ROS. Furthermore, a combination of NC-6300 and TP-HIFU is useful for minimally invasive cancer therapy with cooperative effects of HIFU-derived features, antitumor activity of EPI, and increased ROS generation to cause damage to cancer cells.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Condition:   Hematologic Cancer Intervention:   Drug: Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile Sponsor:   University of California, San Diego Recruiting
Source: - Category: Research Source Type: clinical trials
ConclusionMost cases and fatalities of myocarditis occurred shortly after initiation of immune checkpoint inhibitor therapy. Arrhythmias, particularly complete heart block, appear to be related to the occurrence of more severe and fatal cases. The use of serial electrocardiograms or biomarkers of myocardial injury may be crucial in detecting early stages of the disease process. Further research establishing more specific guidelines is necessary in dealing with this potentially fatal side effect.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Government | Health Management | Science